Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 2/20 | 0.43 |
| ▸ | PPARA | Q07869 | 3/20 | 0.42 |
| ▸ | PPARG | P37231 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25818112 | 0.90 | MTNR1A (0.43) | BCHEPPARAPPARGCYP2D6MTNR1A | |
| SCHEMBL13881720 | 0.88 | CHRM2 (0.48) | BCHEPPARAPPARGCYP2D6MTNR1A | |
| SCHEMBL4568761 | 0.86 | PPARA (0.51) | BCHEPPARAPPARGCYP2D6KCNH2 | |
| SCHEMBL2208855 | 0.85 | TAAR1 (0.45) | BCHEPPARAPPARGCYP2D6 | |
| SCHEMBL3964848 | 0.83 | CYP4F2 (0.44) | BCHEPPARAPPARG | |
| SCHEMBL13881576 | 0.82 | BCHE (0.42) | BCHEPPARAPPARGCYP2D6MTNR1A | |
| SCHEMBL25820080 | 0.81 | CYP2D6 (0.56) | PPARAPPARGCYP2D6KCNH2 | |
| SCHEMBL25822164 | 0.81 | CYP1A2 (0.43) | CYP2D6MTNR1AMTNR1B | |
| SCHEMBL20318730 | 0.81 | PPARA (0.49) | BCHEPPARAPPARGCYP2D6KCNH2 | |
| SCHEMBL20332390 | 0.81 | TAAR1 (0.43) | BCHEPPARAPPARGCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | BCHE 1649/4885PPARA 563/4885PPARG 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.